Targeted and Immunotherapeutic Regimens for Advanced Solid Tumors
This community focuses on the clinical development and evaluation of systemic treatments for advanced solid tumors, specifically non-small-cell lung cancer, urothelial carcinoma, and head and neck squamous cell carcinoma.
The research is dominated by phase III clinical trials assessing the efficacy and safety of combining platinum-based chemotherapy with immune checkpoint inhibitors or targeted agents. Recurring themes include first-line treatment strategies for metastatic disease, perioperative interventions for resectable tumors, and the management of resistance to tyrosine kinase inhibitors. Specific therapeutic modalities frequently cited include pembrolizumab, osimertinib, and durvalumab, applied to populations with EGFR mutations, KRAS G12C mutations, or HER2 expression. The work centers on defining optimal sequencing of therapies and identifying biomarkers that predict response in patients with locally advanced or metastatic disease.
The largest share of the community's output is found in platinum research, accounting for 4.9% of all platinum research and 1,281 papers within this group.
The community comprises 4,682 papers, publishing most frequently in the Journal of Clinical Oncology, Frontiers in Oncology, and Cancers.
Recent work continues to focus on novel combinations for EGFR-mutated lung cancer and HER2-expressing urothelial cancer, including trials of osimertinib plus chemotherapy and disitamab vedotin plus toripalimab.
Papers behind this description
- Non-small-cell lung cancer — Nature Reviews Disease Primers, 2024 — doi:10.1038/s41572-024-00551-9
- Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer — New England Journal of Medicine, 2025 — doi:10.1056/nejmoa2415434
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer — New England Journal of Medicine, 2023 — doi:10.1056/nejmoa2302983
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer — New England Journal of Medicine, 2023 — doi:10.1056/nejmoa2304875
- Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC — New England Journal of Medicine, 2023 — doi:10.1056/nejmoa2306434
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines — European Urology, 2023 — doi:10.1016/j.eururo.2023.08.016
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer — New England Journal of Medicine, 2024 — doi:10.1056/nejmoa2408154
- Lung cancer statistics, 2023 — Cancer, 2024 — doi:10.1002/cncr.35128
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy — New England Journal of Medicine, 2025 — doi:10.1056/nejmoa2502099
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer — New England Journal of Medicine, 2024 — doi:10.1056/nejmoa2404873
- Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends — Signal Transduction and Targeted Therapy, 2023 — doi:10.1038/s41392-023-01522-4
- Bladder cancer — Nature Reviews Disease Primers, 2023 — doi:10.1038/s41572-023-00468-9
- Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC — New England Journal of Medicine, 2025 — doi:10.1056/nejmoa2510308
- Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer — New England Journal of Medicine, 2025 — doi:10.1056/nejmoa2511648
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer — New England Journal of Medicine, 2026 — doi:10.1056/nejmoa2511674
- Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study — Journal of Clinical Oncology, 2025 — doi:10.1200/jco-25-00036
- LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study — Annals of Oncology, 2025 — doi:10.1016/j.annonc.2025.09.124
- ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC) — Annals of Oncology, 2025 — doi:10.1016/j.annonc.2025.09.017